159 related articles for article (PubMed ID: 16084028)
1. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
Berger R
Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
[No Abstract] [Full Text] [Related]
2. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.
McClure R; Mai M; Lasho T
Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039
[No Abstract] [Full Text] [Related]
3. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
Greiner TC
Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
[No Abstract] [Full Text] [Related]
4. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
[TBL] [Abstract][Full Text] [Related]
5. A unifying mutation in chronic myeloproliferative disorders.
Goldman JM
N Engl J Med; 2005 Apr; 352(17):1744-6. PubMed ID: 15858182
[No Abstract] [Full Text] [Related]
6. JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders.
Bellosillo B; Besses C; Florensa L; Solé F; Serrano S
Leukemia; 2006 Apr; 20(4):736-7. PubMed ID: 16453004
[No Abstract] [Full Text] [Related]
7. Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases.
Vannucchi AM; Guglielmelli P; Antonioli E; Mappa S; Pancrazzi A; Bogani C; Ponziani V; Bosi A
Br J Haematol; 2006 Mar; 132(5):652-4; author reply 654. PubMed ID: 16445842
[No Abstract] [Full Text] [Related]
8. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
9. The V617F JAK2 mutation and the myeloproliferative disorders.
Percy MJ; McMullin MF
Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
[TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
McLornan D; Percy M; McMullin MF
Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
[No Abstract] [Full Text] [Related]
11. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients.
Vizmanos JL; Ormazábal C; Larráyoz MJ; Cross NC; Calasanz MJ
Leukemia; 2006 Mar; 20(3):534-5. PubMed ID: 16408096
[No Abstract] [Full Text] [Related]
12. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.
Rossi D; Deambrogi C; Capello D; Cerri M; Lunghi M; Parvis G; Saglio G; Gaidano G; Cilloni D
Br J Haematol; 2006 Oct; 135(2):267-8. PubMed ID: 16956348
[No Abstract] [Full Text] [Related]
13. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
Bousquet M; Brousset P
Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
[No Abstract] [Full Text] [Related]
14. Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders.
Pesu M; O'Shea J; Hennighausen L; Silvennoinen O
Mol Interv; 2005 Aug; 5(4):211-5. PubMed ID: 16123535
[No Abstract] [Full Text] [Related]
15. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
[TBL] [Abstract][Full Text] [Related]
16. JAKing up hematopoietic proliferation.
Shannon K; Van Etten RA
Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
[TBL] [Abstract][Full Text] [Related]
17. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
Ma W; Kantarjian H; Verstovsek S; Jilani I; Gorre M; Giles F; Cortes J; O'Brien S; Keating M; Albitar M
Br J Haematol; 2006 Aug; 134(3):341-3. PubMed ID: 16787500
[No Abstract] [Full Text] [Related]
18. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
Spivak JL; Moliterno AR; Silver RT
N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
[No Abstract] [Full Text] [Related]
19. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
Lasho TL; Mesa R; Gilliland DG; Tefferi A
Br J Haematol; 2005 Sep; 130(5):797-9. PubMed ID: 16115143
[No Abstract] [Full Text] [Related]
20. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
